The Centre for Clinical Trials | Oakvile, Canada

Research site
1344 Cornwall Road, Oakville, Ontario, Canada
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site


10 of 23
Status: Active
Trial type: Interventional
Funder type: Industry

Locations recently updated
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental viti...

Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Ritlecitinib
Drug: Placebo

The co-primary objectives of the study are to:Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Validated Invest...

Active, not recruiting
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

The cumulative effect of aging and environmental exposures (ie, ultraviolet, infrared, and visible light radiation and pollution) leads to wrinkles,...

Active, not recruiting
Mid Face Volume Deficit
Device: HArmonyCa Lidocaine Injectable Gel

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo
Status recently updated

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of ado...

Active, not recruiting
Atopic Dermatitis
Drug: Placebo
Drug: Upadacitinib

Visit the study website https://dawnacnescarstudy.com/ACT for more information. Atrophic acne scars are flat, indented or with an inverted center sca...

Atrophic Acne Scars
Other: Saline Control
Device: ELAPR002f Injectable Gel

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in a...

Alopecia Areata
Drug: CTP-543

This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescen...

Active, not recruiting
Alopecia Areata
Biological: Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine
Drug: PF-06651600

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 100 mg
Drug: Placebo

Trial conditions

Atopic Dermatitis (7 trials)
Dermatitis (7 trials)
Eczema (7 trials)
Alopecia (6 trials)
Alopecia Areata (6 trials)
Psoriasis (3 trials)
Vitiligo (2 trials)
Atrophy (1 trial)
Lipodystrophy (1 trial)
Rosacea (1 trial)

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems